Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib (Q27852954)

From Wikidata

Jump to navigation Jump to search

scientific article

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Language	Label	Description	Also known as
English	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib	scientific article	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Statements

scholarly article

1 reference

13 November 2016

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib (English)

1 reference

13 November 2016

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

18

0 references

4

0 references

Jonathan E Rosenberg

object named as

Jonathan E Rosenberg

22

0 references

object named as

Leena Gandhi

9

0 references

Philip W. Kantoff

object named as

Philip W Kantoff

20

0 references

15

object named as

Massimo Loda

0 references

19

object named as

Stacey B Gabriel

0 references

Mary-Ellen Taplin

12

object named as

Mary Ellen Taplin

0 references

Levi A Garraway

21

object named as

Levi A Garraway

0 references

Toni K Choueiri

8

object named as

Toni K Choueiri

0 references

David M. Sabatini

17

object named as

David M Sabatini

0 references

Sabina Signoretti

14

object named as

Sabina Signoretti

0 references

author name string

Nikhil Wagle

1

0 references

Brian C Grabiner

2

0 references

Eliezer M Van Allen

3

0 references

Susanna Jacobus

5

0 references

Jeffrey G Supko

6

0 references

Michelle Stewart

7

0 references

James M Cleary

10

0 references

Aymen A Elfiky

11

0 references

Edward C Stack

13

0 references

Geoffrey I Shapiro

16

0 references

publication date

May 2014

0 references

Cancer Discovery

1 reference

4

0 references

546-53

0 references

5

0 references

Mutational heterogeneity in cancer and the search for new cancer-associated genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

mTOR kinase structure, mechanism and regulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

Genome sequencing identifies a basis for everolimus sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

20 March 2017

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

7 April 2017

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

7 April 2017

Genomics-driven oncology: framework for an emerging paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Safety and feasibility of targeted agent combinations in solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Activating mutations of TOR (target of rapamycin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Isolation of hyperactive mutants of mammalian target of rapamycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

29 September 2017

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

27 November 2018

Phase I trial of pazopanib in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122326

27 November 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852954&oldid=1790864035"